Patients with paraneoplastic neurological degenerations (PND) develop immune responses to tumor cell antigens that normally are expressed only in neurons (onconeural antigens), leading to effective anti-tumor immune responses (Anderson et al., 1988; Dalmau et al., 1990; Darnell and DeAngelis, 1993) and discrete autoimmune neurological syndromes (Posner and Furneaux, 1990; Darnell, 1994) . These disorders provide unique opportunities to identify neuron-specific genes that are expressed in discrete regions of the brain. High-titer antibodies from several PND syndromes have been used to clone genes encoding onconeural antigens, leading to the identification of proteins expressed in both PND tumors and neurons from affected areas of the nervous system. For example, the Yo antibody, found in patients with cerebellar degeneration and breast or ovarian tumors (Peterson et al., 1992) was used to identify a novel neuronal leucine-zipper protein expressed in cerebellar Purkinje neurons and tumors obtained from these patients (Dropcho et al., 1987; Sakai et al., 1990; Fathallah-Shaykh et al., 1991) . Recoverin, an onconeural antigen targeted in small-cell lung tumors of patients who develop paraneoplastic blindness (Polans et al., 1991; Thirkill et al., 1992) is a protein involved in cGMP-gated receptor signaling in the photoreceptor (Dizhoor et al., 1991; Gray-Keller et al., 1993; Kawamura et al., 1993) . These observations, together with evidence for the active synthesis of antibodies to onconeural antigens in the CSF (Posner and Furneaux, 1990 ) and the detection of T and B cells in the brains of affected patients (Posner and Furneaux, 1990; Hormigo et al., 1994; Jean et al., 1994) antigen recognized by the antisera of patients with paraneoplastic opsoclonus-myoclonus ataxia (POMA), a motor disorder of brainstem, cerebellar, and spinal motor neurons associated with breast cancer. POMA patients harbor high titers of an antibody reactive with a neuronal and tumor cell antigen of 55 kDa (Luque et al., 1991) which was used to clone Noi~l (Buckanovich et al., 1993) . The predicted Nova-l protein has three putative RNA-binding motifs homologous to KH motifs present in hnRNP-K (Buckanovich et al., 1993; Burd and Dreyfuss, 1994) an RBP without a known function (Dreyfuss et al., 1993) . Similar KH motifs also are present in MER-1, a yeast RBP that regulates splicing of the MER-2 gene (Engebrecht et al., 1991; Nandabalan and Roeder, 1995) PSI, a Drosophila RBP that ncgativcly rcgulates P-element mRNA splicing (Siebel et al., 1995) and FMR-I, the fragile-X gene implicated in mental retardation (Ashley ct al., 1993; Gibson et al., 1993; Siomi et al., 1993) . A second family of RBPs (HuCIPLE21, HUD, and Hel-Nl) is a set of target antigens in paraneoplastic encephalomyelopathy-sensory neuropathy (Szabo et al., 1991; Levine et al., 1993; Sakai et al., 1993 ) a spectrum of neurological disorders associated with small-cell lung cancer (Dalmau et al., 1991) . The Hu proteins contain three RNA-recognition motifs that are highly homologous with two Drosophilu proteins, elav, which is essential for neurogenesis (Yao et al., 1993) and sex-lethal, an RBP that regulates alternative splicing and, therefore, sexual differentiation (Baker, 1989 : Valcartel et al., 1993 .
The association of RBPs with several distinct neurological syndromes raises the possibility that interference with the function of neuronal RBPs (n-RBPs) leads to human neurological disease. Evidence in support of this suggestion comes from the characterization of FMR-1, which was defined as an RBP by its ability to bind to ribohomopolymers in vitro (Siomi et al., 1993 (Siomi et al., , 1994 . A single individual with severe mental retardation was found to have a point mutation within one KH domain (DeBoulle et al., 1993) , and this mutation disrupts ribohomopolymer binding in vitro (Siomi et al., 1994) . To examine the role of Nova-l as a target antigen in POMA, we have undertaken an analysis of its function in vitro, and our results suggest several parallels between Nova-l and FMR-1. Both are associated with neurological disease, although only Nova-l is neuron-specific in its expression and associated disease manifestations.
Both bind RNA with similar sequence specificity in vitro; this activity maps to the KH domains of both proteins and is abrogated by analogous point mutations within them. Moreover, we have found that a hallmark of POMA is that disease antisera recognize only functional (RNA-binding) Nova-l KH3 domains, and that affinity-purified POMA antibody blocks Nova-l RNA binding. Taken together, these data support the hypothesis that disruption of n-RBP function generates some human neurological disorders. RNA-prorein filter-binding assn)'. Fusion protein ( 100 ng) was incubated in the indicated concentrations of affinity-purified antibody and bovine strum albumin for 30 min at room temperature in 100 ~1 of binding buffer (250 mM LiCI, 20 mM Tris, pH 7.4, and IO mM MgCI,).
MATERIALS AND METHODS
"P end-labeled riboguanosine (rG; 100 ng) was added and incubated for 2.5 min at room temperature. Samples were vacuum-filtered through 0.2 WM nitroccllulose, washed with I volume of cold binding buffer, and analyzed in a scintillation counter.
RESULTS
Nova-l expression is restricted to a subset of neurons Nova antigens have been reported previously to bc restricted to the CNS (Buckanovich et al., 1993; Graus et al., 1903) . To determine whether Nova protein is restricted to neurons, WC labeled adult mouse brain sections with anti-GFAP and affinity-purified POMA antibodies. Double-label immunofluorescence analysis revealed that GFAP and Nova antigen expression is mutually exclusive throughout the CNS (Fig. 1A ) (data not shown). Nova antigen expression is confined primarily to neuronal nuclei which, together with data presented below, suggests that Nova functions as a nuclear RBP. To confirm that the cells recognized by POMA antibodies were neurons, we performed double-labeling experiments with affinity-purified POMA antibodies and either antineural cell adhesion molecule (NCAM) or anti-neuron-specific enolase (NSE) antibodies. Nova antigen is expressed in all cells recognized by NCAM (Fig. IB,C) and NSE (data not shown). These results, together with the demonstration that Nova protein expression is absent from white matter tracts (Buckanovich et al., 1993) demonstrate that expression of the Nova antigen is neuron-specific.
The specificity of neurological dysfunction (oculomotor-brainstem-cerebellum) in POMA (Posner and Furneaux, 1990; Darnell, 1994) contrasts with reports that the Nova antigen is expressed in all CNS neurons (Luquc et al., 1YYl; Graus et al., 1993) . This may be explained in part by the identification of a second, closely related Nova gene (NOW-~) (Buckanovich et al., 1993) (R. B. Darnell, Y. Y. L. Yang, and G. L. Yin, unpublished data). Thus, we examined Nova-l expression in mouse brain by irl situ hybridization with Nova-l gene-specific probes. These data revealed striking regional localization of NWU-I mRNA expression in ventral diencephalon, midbrain, cerebellum, and hindbrain. Expression was strongest in the midbrain and pontine tegmentum, optic tectum (Fig. lD,E) , and deep cerebellar nuclei (data not shown). There was a distinct absence of reactivity in similar results were observed using a coding-region probe at high stringency (data not shown). Reactivity (whlfe) is observed in the rhinencephalon (R), hypothalamus and preoptic area (H), pons (P), midbrain (M/J), cerebellum (Cb), and medulla (M). No reactivity was detected in the neocortex (N) or thalamus (0, and no reactivity was observed with a sense riboprobe (data not shown). E, High-power exposure of a coronal section at the level of the cerebellum and medulla. Nova-l reactivity is observed in all neurons of the medulla as well as in the Purkinje and granule cells of the cerebellum.
There is no reactivity in white matter tracts [e.g., in the pyramidal tract (&)I.
----
and white matter tracts (Fig. lD,E) . Thus, the expression of the Nova-l gene is restricted to neurons within discrete regions of the mammalian CNS, in a pattern that correlates with the presence of brainstem and cerebellar symptoms and the absence of sensory or neocortical symptoms observed in POMA patients.
Nova-l is an RBP Nova-l encodes three potential RNA-binding domains (RBDs) homologous to the KH domains of hnRNP-K, FMR-1, the Drosophila alternative splicing factor PSI and Bicaudal-C proteins, the yeast alternative splicing factor MER-1, and others (Burd and Dreyfuss, 1994) (Fig. 2) . This domain appears to be a functional protein motif in viva: a severely affected fragile-X syndrome patient harbors a point mutation (1367N substitution) within the core of the conserved KH element (DeBoulle et al., 1993 ) (see Fig. 2 ). Similarly, mutations of the core of the third KH domain of Bicaudal-C leads to loss of function in vivo (Mahone et al., 1995) and mutations in the KH domains of hnRNP-K and FMR-1 decrease RNA-binding activity in vitro (Siomi et al., 1994) . Putative RBPs have been functionally characterized and classified based on their ability to bind ribohomopolymers in vitro (Swanson and Dreyfuss, 1988; Dreyfuss et al., 1993; Burd and Dreyfuss, 1994) . To determine whether Nova-l binds to RNA in vitro, we analyzed the ability of a T7 epitope-tagged NFP to bind ribohomopolymers.
Binding was detected by Western blot analysis Input (nM) Bound (nM) using a monoclonal antibody directed against the T7 epitope. At low stringency (0.25 M NaCl), NFP bound all ribohomopolymers except rA, whereas control proteins showed no detectable binding. At intermediate stringency (0.5 M NaCl) NFP bound preferentially to rG and rU, and at high stringency (0.75 M NaCl) NFP bound only to rG (Fig. 3A) . Thus, Nova-l binds RNA in vitro and binds with the same ribonucleotide preference as FMR-1 (rG > rU >> rA and rC), in contrast to the binding preference (rC) of hnRNP-K and several other KH-type RBPs.
To quantitate NFP binding to rG, we mixed increasing concentrations of protein with constant concentrations of RNA, separated bound from unbound protein, and quantitated the results using Western blot analysis. Binding plots revealed that NFP bound to rG with high affinity in a saturable manner. Using Scatchard analysis, we estimate that NFP bound to rG with a dissociation constant (&) of 250 nM in 0.25 M NaCl (Fig. 3&C) . The affinity of Nova-l for rG is similar to that observed for other RBPs bound to ribohomopolymers (e.g., -200 nM for the polypyrimidine tract-binding protein) (McCarthy and Kollmus, 1995) .
To define the domain of Nova-l that binds to RNA in vitro, we constructed several truncated Nova-l fusion proteins. One protein (Nl) encompasses the N terminus and first KH motif of Nova-l; a second (N1"4T) is identical to Nl but harbors an isoleucine-+threonine mutation at position 14 of the first KH motif; a third (N3) encompasses the third KH domain and C terminus of Nova-l; and a fourth (N3L2'N) is identical to the N3 Figure 3 . Nova-l binds RNA in vitro. A, T7-tagged Nova-l NFP was bound to the indicated ribonucleotide homopolymers at varying salt concentrations; after washing, bound protein was detected by Western blot analysis using a T7 monoclonal antibody (A, G, C, and U binding assays are shown in lanes 2,3,4, and 5, respectively). NFP bound to G, C, and U ribohomopolymers in 0.25 M NaCI, to rG and rlJ in 0.5 M NaCI, and only to rG in 0.75 M NaCI. NFP bound to all four ribohomopolymers in 0.1 M NaCl (data not construct but harbors a leucine-+asparagine mutation in position 21 of the third KH motif (Fig. 2) . The N31d21N mutation is precisely analogous to the FMR-1 1367N in vivo KH domain mutation (see Fig. 2 ). Ribohomopolymer-binding assays demonstrated that both Nl and N3 maintained the same sequence preference (rG > rU) as the NFP, whereas N1"4T and N3L2'N showed markedly reduced RNA binding to rG (Fig. 4A ) (data not shown). Quantitation of N3 and N3L2'N binding to rG demonstrated that N3 has a >25-fold affinity for rG than N3L2'N (N3, & -750 nM; N3"lN, Kd -20 PM; Fig. 4B,C) .
As an independent measure of Nova-l RNA binding, Northwestern assays were performed. NFP, N3, N3',"N, and a control fusion protein were immobilized on nitrocellulose and probed with a poly-rG riboprobe. NFP and N3 bound to the rG riboprobe, whereas N3r21N and the control fusion protein did not (Fig. 5) . The blot was stripped and reprobed with T7 antibody, revealing fusion protein present in each lane (Fig. 5 ). These experiments demonstrate that the Nova-l KH domain is sufficient for sequence-specific binding to RNA in vitro, and that disruption of this domain markedly interferes with that binding.
To determine whether Nova-l is capable of binding to in vivo brain RNAs, we incubated NFP with total mouse brain RNA. After immunoprecipitating NFP, RNA binding was detected by amplifying specific RNAs using reverse-transcription PCR. Using this analysis, NFP selectively bound some (Nova-l and actin), but not all (P-NAP), abundant neuronal RNAs examined (Fig. 6) . No Input (PM) Bound (nM)
bound RNA was detectable after immunoprecipitation of an irrelevant protein or after mock immunoprecipitation of NFP with normal human serum. These results demonstrate that Nova-l is able to bind in vivo brain RNAs. Because several RBPs bind to ssDNA as well as ribohomopolymers in vitro (Dreyfuss et al., 1993) , we examined whether Nova-l was able to bind to ssDNA. Although control proteins showed no detectable binding, NFP stably interacted with ssDNA even under stringent conditions (4 M NaCl; Fig. 7A ). Similarly strong interactions have been observed between ssDNA and hnRNP-K or FMR-1 (Dreyfuss et al., 1993) . Unlike NFP, neither Nl nor N3 isolated KH domain protein-bound ssDNA (Fig. 7B) . These results suggest that the Nova-l KH domains function preferentially as RBDs.
Autoimmune antisera bind the functional Nova-l RNA-binding motif It has been suggested that autoimmune epitopes map to functional domains of target proteins (Tan, 1991) . Because we have defined the Nova-l KH domain as a functional RBD in vitro and previously have mapped the target epitope of POMA autoimmune sera to the third KH domain of Nova-l (Buckanovich et al., 1993), we examined whether there was a relationship between the function of Nova-l and the binding of POMA antisera to the protein. Western blot analysis of the Nl and N3 proteins confirmed that N3 encoded the autoimmune epitope (data not shown). When increasing amounts of N3 or N3L2'N protein were blotted with autoimmune POMA antiserum, we found that N3 was recognized markedly better than the N3L21N point mutant (Fig. &I) . To confirm that equal amounts of N3 and N3L2'N protein were present in the assay, the blot was stripped and reprobed with a T7 monoclonal antibody (Fig. 84) . To extend this result, made with a single POMA antiserum, we repeated this analysis with five additional POMA antisera. In each case, reactivity was robust with N3 fusion protein but was nearly undetectable with the N3=*lN protein (Fig. 8B) . These results indicate that the same amino acid that is essential for the RNA-binding activity of N3 is also essential for recognition of the protein by autoimmune antibodies.
The dependence of both RNA binding and antibody recognition on the same amino acid suggests that the autoimmune POMA antibody may inhibit the function of the Nova-l protein. To test this hypothesis in vitro, we assessed the ability of Nova-l protein to bind soluble ribohomopolymers in the presence of antibody using a filterbinding assay. Binding of N3 to rG was inhibited by affinity-purified , 1996, 76(3):1114-1122 1119 Northwestern Western Figure 5 . Northwestern blot analysis of Nova-l RNA binding. NFP (Iurge arrow) and N3 (small arrow), N3L2'N, or a Control protein were transferred to nitrocellulose and bound to a poly-rG riboprobe (NorthWestem) . RNA bound only to NFP (large arrow) and N3 (small arrow). Some nonspecific binding to bacterial proteins is present in the wells of all lanes. To confirm that approximately equal amounts of fusion protein were loaded in each lane, the blot was stripped and reprobed with a T7 monoclonal antibody (Western) .
POMA antibodies in a dose-dependent manner (Fig. 8C) . However, N3 binding was unaffected by T7 monoclonal or irrelevant autoimmune antibodies. In contrast, Nl, which is not recognized by POMA antibodies, bound rG equally well in the presence of POMA or control antibodies. Surprisingly, POMA antibody inhibited NFP (which contains both Nl and N3 sequences) RNA binding as effectively as it inhibited N3 (Fig. 6C) . Taken together, these results indicate that the binding of POMA antibody to N3 effectively prevents the NFP from binding to RNA.
DISCUSSION
We have determined that the Nova-l paraneoplastic disease antigen is an n-RBP. The expression pattern of Nova-l mRNA and the Nova antigen appear to be restricted entirely to neurons of the CNS in the adult (Fig. 1) Figure 6 . Nova binds in vivo RNA. NFP or a T7-tagged control fusion protein (Yo) were incubated with total mouse brain RNA. NFP was immunoprecipitated with either POMA sera (NFP; lanes 5 and 6) or normal human sera (Mock; lanes 3 and 4); control protein was immunoprecipitated with a T7-tagged monoclonal antibody (Yo; lanes 1 and 2). Bound RNAs were extracted, reverse-transcribed, and PCR-amplified using gene-specific primers to Nova-l, actin, or P-NAP (an abundant neuron-specific mRNA; see Newman et al., 1995) . To ensure RNA integrity, total brain RNA also was amplified by reverse transcriptase (RT)-PCR (+Control, lane 7). As a control for DNA contamination, each RNA sample was analyzed in duplicate with (+) or without (-) RT. NFP bound to Nova-l and actin, but not to P-NAP RNA. 1993) (R. Buckanovich and R. Darnell, unpublished data) mouse. Similarly restricted neuronal localization for RBPs has been described for only two other gene families. The first family contains three RNP-motif RBDs (Dreyfuss et al., 1993) and is comprised of the Drosophila genes elav and rbp9 (Campos et al., 198.5; Kim and Baker, 1993; Yao et al., 1993) and their mammalian homologs, the HU (Szabo et al., 1991) and He&N1 (Levine et al., 1993; Ring et al., 1994) genes in mouse, and the elr genes in Xenopus laevis (Good, 1995) . A second family of n-RBPs, containing two RBDs, includes the Xenopus laevis nrp-1 (Richter et al., 1990) and Drosophila musashi (Nakamura et al., 1994) genes, which are homologous to the hnRNP A/B proteins (Dreyfuss et al., 1993; Nakamura et al., 1994) . The members of these two n-RBP families have been characterized as being specifically but ubiquitously expressed in neurons of the central and peripheral nervous systems, suggesting involvement in neuronal, but not regional, specification and function within the brain. Other RBPs, including FMR-1 (Abitbol et al., 1993; Devys et al., 1993; Hanzlik et al., 1993; Hinds et al., 1993) and cpo (Bellen et al., 1992) , may show some regional variation of expression within the nervous system, but also are expressed in cell types other than neurons. Nova-l is unique in being the first n-RBP with a tightly defined region-specific pattern of expression within the mammalian CNS. The restricted subcortical expression of Nova-l is not only compatible with the restricted nature of POMA but also suggests that n-RBPs perform specific roles in the development or function of discrete groups of neurons.
RBPs play important roles in post-transcriptional regulation of RNA metabolism, ranging from splicing and editing to transport, Figure 7 . NFP, but not Nl or N3, binds ssDNA. A, NFP was bound to ssDNA in the presence of increasing salt (0.1-4.0 M NaCl); bound protein was assayed as described in Figure 3 . Twenty percent of the amount of protein used in each binding assay was loaded as a control (+). B, The binding of equimolar amounts of NFP, NI, and N3 to SSDNA was compared under relatively nonstringent conditions (0.25 M NaCl). Under these conditions NFP bound ssDNA, whereas Nl and N3 did not. Twenty percent of the amount of protein used in each binding assay was loaded as a control (+). Pinol-Roma and Dreyfuss, 1992; Dreyfuss et al., 1993; Burd and Dreyfuss, 1994; McCarthy and Kollmus, 199.5) . Recently, two KH-type RBPs have been functionally defined to be involved in regulating alternative splicing. The yeast MER-1 protein, which has one KH domain, has been demonstrated to be essential for the meiosis-specific splicing of the MER-2 transcript (Engebrecht et al., 1991; Nandabalan and Roeder, 1995) although a specific RNA sequence with which the protein interacts has not been defined. The Drosophila PSI protein, which was cloned recently and was reported to have three KH domains, inhibits functional splicing of the P-element transposase in somatic tissues (Siebel et al., 1995) . Based on the homology of Nova-l to these proteins, it is possible that Nova-l is involved in regulating neuron-specific alternative splicing. However, other roles also have been attributed to KH-type RBPs; the Bicaudal-C protein, for example, which harbors five KH domains, has been indirectly implicated in RNA targeting (Mahone et al., 1995) . Clarifying the role of Nova-l in neurons awaits clearer identification of the RNA ligands to which it binds. The demonstration that Nova-l and isolated Nova-l KH proteins bind RNA, and that point mutations within these proteins disrupt RNA binding, defines the KH motif as a functional domain of Nova-l. The observation that POMA antibody recognizes the third KH domain of Nova-l, but not an inactive point mutant, is consistent with the general observation that autoantibodies are unusual in recognizing functionally important domains (Tan, 1991) . The Nova-l KH motifs share sequence similarity and in vitro RNA-binding specificity with FMR-1, and mutations that abrogate RNA binding of Nova-l and FMR-1 localize to the same amino acid within the KH domains. These observations suggest that Nova-l and FMR-1 interact with similar RNA ligands in neurons. Moreover, interference with specific RNA binding may A.
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be important in the pathogenesis of the neurological syndromes associated with both FMR-1 (Ashley et al., 1993; Siomi et al., 1994) and POMA. A single severely affected patient harbors a point mutation within the second FMR-1 KH domain (DeBoulle et al., 1993) , and this mutation reduces the interaction of FMR-1 with RNA in vitro (Siomi et al., 1994) . Because affinity-purified POMA antibodies inhibit the in vitro RNA-binding activity of Nova-l (Fig. S) , we propose that interference with the RNAbinding activity of Nova-l may lead to neurological disease, similar to the proposed pathogenesis of FMR-1, but via an immunemediated rather than a genetic mechanism. A compelling role for the isolated Nova-l KH motifs as functional RBDs reflects earlier studies of the hnRNP-K and FMR-1 proteins, but differs in several respects. Although KH domains are necessary for RNA binding in the intact hnRNP-K and FMR-1 proteins (Siomi et al., 1993 (Siomi et al., , 1994 , our data provide the first evidence that they are sufficient for direct interaction with RNA in vitro (Dreyfuss et al., 1993; Burd and Dreyfuss, 1994; Siomi et al., 1994) . Quantitative analysis of the RNA binding of full-length versus isolated Nl and N3 KH domains of Nova-l reveals that they are competent to bind RNA with nearly equal affinity (& -250-750 nM in 0.25 M NaCl; Figs. 3, 4) (data not shown). These results provide a plausible mechanism for interaction of RNA with proteins (such as MER-1) that contain single KH domains.
POMA antibody, which binds only to the third KH domain (Buckanovich et al., 1993) (R. Buckanovich and R. Darnell, unpublished data), abolishes the Nova-l-RNA interaction, even in the presence of two upstream RBDs (Fig. 8) . This may be explained if the Nova-l KH domains are in close physical proximity, such that the presence of antibody bound to the third Nova-l KH domain is able to inhibit the interaction between RNA and the first and second Nova-l KH domains sterically.
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8 Antibody POMA-1 F&re 8. POMA antisera recognize wild-type N3, but not the N3L2'N point mutant, and inhibit RNA binding in T7 vitro. A, Western blot analysis of 12.5, 25,50, and 100 ng of N3 (lanes 14) and N3L2'N (lanes 5-8) using a POMAdisease antiserum (POMA-I) or T7 monoclonal antibody (7'7). B, Western blot analysis with T7 monoclonal antic. body and-five additional POMA-disease antisera (POMA 2-6) with 50 ne of N3 and N3'-'jN proteins.'C, RNA biiding of NFP, and N3 proteins preincubated with affinity-purified POMA or irrelevant autoimmune (Control) antibodies. Neither NFP nor N3 RNA binding is affected by control antibodies; however, both are inhibited in a dose-dependent manner by POMA antibodies. POMA antibodies do not recognize Nl and have no affect on Nl RNA binding. Dilution of antibodv used is indicated on the x-axis; Antibody Dilution
